The science of viral vector manufacturing is generating a lot of excitement, and companies in this space are under pressure to move fast and make cost-effective decisions; this can occasionally result in speed at the expense of due diligence.
Multimodal manufacturing optimizes product combinations based on manufacturing and regulatory similarity and compatibility. Manufacturers must produce a variety of Advanced Therapy Medicinal Products (ATMPs) quickly and efficiently. Why not design a multi-modal ATMP facility?
All eyes are on those on the front lines seeking to develop and produce new drugs. There’s unprecedented pressure to offer both immediate treatments for those affected and long-term biotherapies and vaccines to prevent future epidemics.
Interview with Niranjan Kulkarni, Senior Director, Allan Bream, Process Specialist, and Grace Linton, Process Architect at CRB that originally appeared in Cell and Gene Therapy Insights, on how commercial biopharma experience is shaping cell and gene therapy facility design.